Table 3 Clinical outcomes
From: Tranexamic acid may benefit patients undergoing total hip/knee arthroplasty because of haemophilia
Demographics | Mean and Standard Deviation | p Value | |
|---|---|---|---|
Non-TXA Group (N = 18) | TXA Group (N = 16) | ||
Knee | N = 12 | N = 12 |  |
 ROM (Flexion/Extension) at discharge (°) | 92.9 ± 5.0 | 100.8 ± 6.7 | 0.004 |
 ROM (Flexion/Extension) at 1-year follow-up (°) | 92.5 ± 4.0 | 100.0 ± 7.0 | 0.004 |
 ROM (Flexion/Extension) at final follow-up (°) | 95.0 ± 3.0 | 101.3 ± 7.1 | 0.013 |
 KSS score at discharge | 79.2 ± 6.7 | 86.2 ± 5.4 | 0.023 |
 KSS score at 1-year follow-up | 82.2 ± 5.0 | 88.1 ± 5.5 | 0.026 |
 KSS score at final follow-up | 83.0 ± 5.2 | 88.2 ± 5.7 | 0.028 |
Hip | N = 10 | N = 8 |  |
 ROM (Flexion/Extension) at discharge (°) | 102.5 ± 8.2 | 113.1 ± 9.6 | 0.027 |
 ROM (Flexion/Extension) at 1-year follow-up (°) | 105.5 ± 4.4 | 113.8 ± 5.8 | 0.006 |
 ROM (Flexion/Extension) at final follow-up (°) | 104.0 ± 5.2 | 111.3 ± 6.4 | 0.022 |
 ROM (Internal−/External-Rota) at discharge (°) | 39.0 ± 7.4 | 61.9 ± 6.5 | < 0.001 |
 ROM (Internal−/External-Rota) at 1-year follow-up (°) | 39.0 ± 11.0 | 68.8 ± 9.9 | < 0.001 |
 ROM (Internal−/External-Rota) at final follow-up (°) | 40.5 ± 6.0 | 65.6 ± 7.8 | < 0.001 |
 ROM (Adduction/Abduction) at discharge (°) | 48.0 ± 12.3 | 62.5 ± 15.8 | 0.053 |
 ROM (Adduction/Abduction) at 1-year follow-up (°) | 50.5 ± 9.7 | 55.0 ± 22.4 | 0.622 |
 ROM (Adduction/Abduction) at final follow-up (°) | 50.5 ± 10.1 | 55.0 ± 21.8 | 0.658 |
 HHS score at discharge (°) | 76.5 ± 10.1 | 86.1 ± 4.6 | 0.036 |
 HHS score at 1-year follow-up (°) | 78.8 ± 8.8 | 88.1 ± 5.5 | 0.020 |
 HHS score at final follow-up (°) | 80.5 ± 7.7 | 89.1 ± 4.5 | 0.017 |